VIMIANNasdaq StockholmHealth CareIFRS · SEK

Vimian Group

Vimian Group is a company focused on the animal health sector, providing a range of products and services across four segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company is known for its innovative solutions in veterinary dental care and has achieved significant growth in its Specialty Pharma segment. Vimian operates globally, with a strong presence in Europe and North America, and is headquartered in Stockholm, Sweden. The company is committed to advancing its market position through organic growth and strategic acquisitions.

Ask about the company
Revenue425m SEK
+760.3 %y/y
Operating profit (EBIT)66.8m SEK
+35.8 %y/y
EBIT margin15.7%
−83.9 ppy/y
Net income32.3m SEK
+67.4 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

0100200300400500m SEK2021: 173 m SEK2021: EBIT 41 m SEK20212022: 281 m SEK2022: EBIT 39 m SEK20222023: 332 m SEK2023: EBIT 41 m SEK20232024: 49 m SEK2024: EBIT 49 m SEK20242025: 425 m SEK2025: EBIT 67 m SEK2025TTM 2026: 467 m SEKTTM467
RevenueOperating profit (EBIT)TTM = last 12 months, not a full fiscal year
Ask Clarifo about Vimian Group

Business

Share of revenue
Specialty Pharma43 %

Includes pharmaceuticals tailored for animal health needs.

MedTech37 %

Comprises medical technology products for veterinary use.

Veterinary Services15 %

Offers services and advice for veterinary professionals.

Diagnostics6 %

Provides diagnostic products for animal health.

Customers

Vimian Group serves a diverse range of customers in the animal health industry, including veterinary professionals, clinics, and pharmacies. The Specialty Pharma segment targets veterinary clinics and pharmacies that require specialized pharmaceuticals for animal care. MedTech solutions are designed for veterinary professionals seeking advanced medical technology for diagnostics and treatment. The Veterinary Services segment provides advice and services to veterinary clinics, enhancing their operational efficiency. Diagnostics products are used by veterinary professionals for accurate animal health assessments.

Veterinary Clinics

Purchase pharmaceuticals and MedTech solutions for animal care.

Pharmacies

Buy veterinary pharmaceuticals due to regulatory needs.

Veterinary Professionals

Use diagnostics and MedTech for advanced animal health care.

Strategy

Vimian Group's strategic priorities include driving strong organic growth and enhancing operational efficiencies. The company is focused on expanding its M&A pipeline to strengthen its market position and enter new niches, such as veterinary dental care. Vimian aims to create the best workplace environment to attract and retain top talent. Additionally, the company plans to list on the Nasdaq Stockholm Main Market to increase its visibility and access to capital.

Organic GrowthMedium term

To enhance market position and revenue.

M&A PipelineMedium term

To enter new market niches and strengthen position.

Nasdaq Stockholm ListingShort term

To increase visibility and access to capital.

Geography

Vimian Group operates globally, with a significant presence in Europe and North America. The company generates substantial revenue from these regions, with Europe being a key market for its Specialty Pharma and MedTech segments. North America is also crucial, particularly for the MedTech and Veterinary Services segments. The company is headquartered in Stockholm, Sweden, and aims to expand its geographic footprint through strategic acquisitions and organic growth.

Risks

Vimian Group faces several risks, including market-specific challenges such as regulatory changes in the animal health sector. The company is also exposed to geographic risks, particularly in North America, where market conditions can affect MedTech sales. Seasonality impacts revenue, especially in the MedTech segment, where the first quarter is typically the strongest. Additionally, the company must manage risks associated with its M&A activities, ensuring successful integration of acquisitions. General industry risks include fluctuations in demand for animal health products and services.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Regulatory Changes1Geographic Exposure3Seasonality4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Regulatory ChangesImpact: HighLikelihood: Low

    Impact on product approvals and market access.

  2. M&A IntegrationImpact: High

    Challenges in integrating new acquisitions.

  3. Geographic ExposureImpact: MediumLikelihood: Low

    North America market conditions affect sales.

  4. SeasonalityImpact: MediumLikelihood: Low

    Affects revenue and operational planning.

Ask Clarifo about Vimian Group

Accounting

Judgemental items
Revenue Recognition

Timing affects reported results across segments.

Impact: high

Seasonality

Impacts quarterly revenue and cost fluctuations.

Impact: medium

Goodwill Accounting

Affects balance sheet valuations post-acquisitions.

Impact: high

Similar listed companies

Publicly listed companies with a comparable business focus.

Viva Wine Group

VIVA · Consumer Staples

Viaplay Group

VPLAY-B · Telecommunications

Dustin Group

DUST · Technology

Orion Oyj

ORNBV · Drug Manufacturers - General

Humble Group

HUMBLE · Consumer Staples

Sampo Oyj

SAMPO · Insurance - Diversified

Last updated: 24/09/2026

Vimian Group (XSTO) – Health Care | Financial Analysis – Clarifo